million and in payment for additional capital of the associate for Baht 1,365 million. • Net cash used in financing activities of Baht 2,379 million resulting from the loan repayment according to the long

deferred revenue. However, during the period 2019, the Company has reconsidered the remaining guarantee EBITDA and found that existing risk and reward were insignificant. The Company has therefore reversed

385.7 (64.1%) Net Profit 406.6 99.3 (75.6%) Normalized Total Revenue/1 3,598.1 1,399.5 (61.1%) Normalized Net Profit/2 285.0 196.5 (31.1%) Normalized Total Revenue excluding Deferred Revenue Item/3

decrease of KEGCO’s financial lease receivable by 2,311 million Baht. The long-term loan receivable from SEG, for convert to equity to purchase of SEGSD, decreased by 839 million Baht. Deferred expenses

one project affecting a reduction of income of Baht 20.51 million and the estimation of penalty charge of one project expected to be delayed affecting a reduction of income of Baht 2.56 million

amortization of intangible assets arising from the purchase of investments in associate companies and the result of associate companies’ delayed revenue recognition due to the delay in delivery of work

for long term growth, while remaining focused on supporting, supplementing and leveraging our flagship business of Combined PET. • With the reopening of economies, easing of lockdowns and improvement in

subsidiary recorded net profit of 3,635 MTHB, increased by 576 MTHB or 18.8% comparing to year 2018, which due to the recognition of deferred tax assets from loss carried forward of the Company and its

revenues for the year 2015 and 2016 were 1.4%. Income Tax Income tax including corporate income tax and derferred tax which derived from the adjustment of deferred tax assets (liabilities). Income tax for

incurred from deferred tax. This extra transaction was included in year ended 2017 financial statement for the net amount of THB 24 million. Revenue from Hospital Operations Revenue from hospital operations